Skip to main content
Evidence Snapshot

Sodium/glucose cotransporter 1

CHEMBL4979 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4979
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sodium/glucose cotransporter 1 as ChEMBL target CHEMBL4979, mapped to UniProt P13866. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sodium/glucose cotransporter 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4979
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P13866
Sodium/glucose cotransporter 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Sodium/glucose cotransporter 1 matters

As of 2026-09-13

Sodium/glucose cotransporter 1 is reviewed as Sodium/glucose cotransporter 1 (UniProt P13866); Sodium/glucose cotransporter 1 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 12 approved drugs, 1552 compounds, and 129 assays, with lead potency reaching pChEMBL 9.8.

Disease context
type 2 diabetes mellitus

Sodium/glucose cotransporter 1 shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include LICOGLIFLOZIN, SOTAGLIFLOZIN.

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include LICOGLIFLOZIN, SOTAGLIFLOZIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 12 approved drugs, 1552 compounds, and 129 assays for this target. The dominant activity type is IC50. CHEMBL485830 is the current potency anchor at pChEMBL 9.8.

Use CHEMBL485830 as the tractability anchor when discussing potency (pChEMBL 9.8).

Activity source · ChEMBL 36 via Core Engine
12 approved pChEMBL 9.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Sodium/glucose cotransporter 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P13866, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why type 2 diabetes mellitus is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1552
Total Compounds
129
Total Assays
12
Approved Drugs
IC50: 2145.0, KI: 47.0, EC50: 78.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL485830
 9.8 IC50 —
No preferred name
CHEMBL521026
 9.8 IC50 —
No preferred name
CHEMBL4297625
 9.3 IC50 Clinical
No preferred name
CHEMBL5835461
 9.2 IC50 —
No preferred name
CHEMBL3690855
 9.2 IC50 —

Approved Drugs

Structure Compound First Approval
SOTAGLIFLOZIN
CHEMBL3039507
 2019
ERTUGLIFLOZIN
CHEMBL1770248
 2017
DAPAGLIFLOZIN
CHEMBL429910
 2012
CANAGLIFLOZIN ANHYDROUS
CHEMBL2048484
 2011
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:44:13Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4979